RECEIVED
CENTRAL FAX CENTER
JUL 28 2008

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 -46. (Cancelled)

47. (New) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form $-C(R_5)=N-$;

Y is $-C(R_5)-$ and taken together with the carbon atom bearing the phenyl group forms a double bond and R_1 is absent;

Y' is $-N(R_5)-$;

Z forms a covalent single bond between X' and Y';

R_2 and R_4 are independently selected from hydrogen and C_{1-3}alkyl;

R_3 is selected from C_{1-3}alkyl and $(A)_mR_{12}$;

$-C(R_5)-$ is selected from $-C(H)-$ and $-C(C_{1-20}$alkyl$)-$;

$-N(R_5)-$ is selected from $-N(H)-$ and $-N(C_{2-20}$alkyl$)-$;

m is 0;

R_{12} is selected from the group consisting of OH, SH, NH_2, halo, NO_2, $C(R_{17})_3$, $OC(R_{17})_3$ and CN;

R_{17} is independently selected from hydrogen and halogen; and

wherein each alkyl may be optionally substituted.

48. (New) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form $-C(R_5)=N-$;

Y is $-C(R_5)-$ and taken together with the carbon atom bearing the phenyl group forms a double bond and R_1 is absent;

Y' is $-N(R_5)-$;

Z forms a covalent single bond between X' and Y';

R_2 and R_4 are independently selected from hydrogen and C_{1-3}alkyl;

R_3 is selected from C_{1-3}alkyl and $(A)_mR_{12}$;

$-C(R_5)-$ is selected from –C(H)- and $-C(C_{1-20}$alkyl$)-$;

$-N(R_5)-$ is selected from –N(alkyl)- wherein alkyl is selected from the group consisting of ethyl, n-propyl, *iso*-propyl, cyclopropyl, n-butyl, *sec*-butyl, *t*-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

m is 0;

R_{12} is selected from the group consisting of OH, SH, NH_2, halo, NO_2, $C(R_{17})_3$, $OC(R_{17})_3$ and CN;

R_{17} is independently selected from hydrogen and halogen; and

wherein each alkyl may be optionally substituted.

49. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Y is –CH-; and

X is –CH-.

50. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R_3 is $OC(R_{17})_3$.

51. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R_3 is C_{1-3}alkyl.

52. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R_3 is $–CH_3$ or $-OCH_3$.

53. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein $N(R_5)$- is 3-methylbutyl.

54. (New) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1*H*-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (New) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1*H*-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (New) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (New) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.